Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.
After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.
An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
These are strong results, and would likely make it hard for the FDA to refuse in a way that withstands arbitrary and capricious review,” said Dorit Reiss, a vaccine policy expert ...
Moderna's mRNA flu vaccine shows greater efficacy than conventional shots in a large trial, boosting hope for mRNA technology ...
Combriax demonstrates strong immunogenicity across age groups, exceeding comparator vaccines for multiple influenza strains ...
By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...
Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.
The results are part of the company’s strategy to “diversify our geographic footprint” and rely less on the US market, Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results